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Chapter 6 
Surgery for Metabolic Liver Disease 
THOMAS E. STARZL 
There is no aspect of intermediary metabolism in 
which the liver is not involved. Consequently, it is 
not surprising that inborn errors of metabolism can 
be influenced by operations on the liver. This 
chapter will describe how the course of liver-based 
inborn errors of metabolism can be changed by 
two kinds of hepatic operations, portacaval shunt 
and liver transplantation. 
Portal Diversion 
Mechanism of Effects 
Venous blood from the splanchnic viscera has 
liver-supporting qualities not found to the same 
degree in other kinds of arterial or venous blood 
(1-6). The main splanchnic venous "hepato-
trophic" factors are almost certainly endogenous 
hormones of which the single most important is 
insulin. Deprivation of the liver of the so-called 
"hepatotrophic effects" of portal blood has been 
noted under several experimental conditions (in-
cluding portacaval shunt) to cause hepatocyte at-
rophy, deglycogenation, and fatty infiltration. 
With electron microscopic studies, relatively spe-
cific findings have been disruption and reduction 
of the rough endoplasmic reticulum (RER) and 
diminution of its lining polyribosomes (1,3-7), 
Since RER is the "factory" of the cell, a consequent 
reduction in many biosynthetic processes would 
be expected. Numerous studies have verified this 
hypothesis. 
For example, the effect of portal diversion on 
hepatic lipid metabolism has been unusually well 
studied. Reductions of more than 80% in hepatic 
cholesterol and/or triglyceride or lipoprotein syn-
thesis have been demonstrated in rats, dogs, 
swine, and baboons (1,3). Reductions in hepatic 
lipid synthesis also have been documented in 
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patients treated by us with portacaval shunt for 
'familial hypercholesterolemia (FH) (8-10), and it 
has been shown that total body cholesterol is 
greatly reduced (10). Thus, lipid homeostasis is 
altered to an extraordinary degree by portacaval 
shunt, with the reduction in hepatic lipid synthesis 
being the greatest change. 
Bile acid synthesis also is greatly reduced by 
portacaval shunt (1,8,10). Another synthetic path-
way that has been well studied after portal diver-
sion is the hepatic urea (Krebs-Henseleit) cycle, 
which has been shown by Reichle et a1. to be 
depressed by Eck's fistula in rats (11) and dogs 
(12). They also demonstrated a reduction in several 
of the enzymes involved in this metabolic path-
way, 
Many studies during the 1970s and mid-I980s, 
summarized elsewhere (1), have shown that por-
tacaval shunt lowers the activity of the hepatic 
microsomal mixed-function enzyme system. Aside 
from illustrating the principle of a wide-ranging 
decline in hepatic metabolic functions after porta-
caval shunt, these observations are of potential 
specific importance because the microsomal 
mixed-function enzyme system, for which multi-
ple cytochrome P450 and P448 species serve as 
terminal oxidases, metabolizes a variety of drugs 
and foreign chemicals, as well as endogenous 
compounds such as steroids and fatty acids. The 
depression of this broad-ranging enzyme system 
would relate to many of the metabolic effects of 
portal diversion. 
Clinical Applications of Portal Diversion 
Portacaval shunt has been used to palliate hepatic-
based inborn errors of carbohydrate, lipid, and 
protein metabolism. Although these were great 
advances at the time, such surgical therapy has 
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Table 6.1. Patients with GSD Treated by Portal Diversion' 
Preoperative Symptoms 
Growth Persistent 
Patient Age GSD Hypogly- Retard- Hypoglycemia SUT1)ival After 
No. (yr) Type Date of Operation cemia Acidosis ation Postoperatively Shunt 
1 8 11I October 15, 1963 Yes Yes Yes No Alive 22V2 years 
2 7 I June 26, 1968 Yes Yes Yes Died 2 days 
3 7 I May 2,1972 Yes Yes Yes Yesh Alive 14 years 
4 11 I May 17, 1972 Yes Yes Yes No Died 43/, years 
5 10 VI August 2, 1972 Yes Alive 13:;;3 years 
6 5 III November 7, 1972 Yes Yes Yes No Alive 13 '12 years 
7 3 III November 8, 1972 Yes Yes Yes Yes" Alive 13'/2 years 
8 8 I August 13, 1973 Yes Yes Yes Yes'" Alive 12¥J years 
9 12 I December 14, 1973 Yes Yes Yes Yes" Alive 12112 years 
10 1 I October 2, 1976 Yes Yes Yes Yes" Alive 9\12 years 
a Patients 1 and 2 had portacaval transposition; all others had portacaval shunt. 
/, Overnight feeding via nasogastric tube starting 211:--4 years after portacaval shunt. 
" Underwent orthotopic liver transplantation February 12, 1982, and is alive 4 years later (see text). 
been rendered obsolete by the even more effective 
procedure of liver transplantation. Nevertheless, 
the information obtained has been important in 
understanding hepatic physiology in humans, and 
will be briefly described here. 
GL YCOGEN STORAGE DISEASE 
Portal diversion was first performed for glycogen 
storage disease more than 20 years ago (13) with a 
rationale that is naive in retrospect. It was hoped 
that by short-circuiting splanchnic venous blood 
around the liver, glucose would be made more 
readily available to peripheral tissues with relief of 
the hypoglycemia caused by glycogen storage dis-
ease (GSD), and that the liver would be coinciden-
tally deglycogenated. The animal experiments 
cited in Mechanism of Effects, above, suggest that 
the consequences of portacaval shunt are far more 
subtle and wide-ranging than this simple view. 
That first patient had type III GSD. She is still 
alive more than 20 years after portacaval transpo-
sition. The bypassed portal venous blood was 
replaced with blood returning from the inferior 
vena cava, an operation which was first described 
in animals by Child et aL (14). The transposition 
was used in order to avoid the potential hazards of 
Eck's fistula. It was appreciated then, and amply 
confirmed since (1,7), that most animals, including 
subhuman primates, develop wasting and enceph-
alopathy after portal diversion, but it was not 
appreciated that humans would be an exception to 
this generalization. 
Two more portacaval transpositions were per-
formed, one by Riddell et al. (15). In Riddell's 
patient, the cavoportal anastomosis clotted (16). 
The other attempt cost the life of our second 
patient; the liver was unable to transmit the re-
routed vena caval flow, causing hepatic swelling 
and uncontrollable acidosis (17). 
Subsequently, the simpler procedure of portaca-
val shunt has been used (16). To our knowledge, 
end-to-side portacaval shunt was used in all later 
patients. By the spring of 1973 (16), our own series 
of patients had reached seven, and six more had 
been formally reported in the literature from other 
centers. Subsequently, our patients increased in 
number to 10. Type I disease (glucose-6-phos-
phatase deficiency) was the indication for treat-
ment in six patients, type III disease (amylo-1, 
6-glucosidase deficiency) in three, and type 6 dis-
ease (phosphorylase deficiency) in one (Table 6.1). 
Metabolic Effects 
Most of the children who had pre-existing hy-
poglycemia did not obtain relief from this problem 
after portal diversion, or the relief was not com-
plete. Thus, night feedings usually had to be 
continued. Studies of plasma insulin and glucagon 
in several of these patients showed marked eleva-
tions of the insulin response to a glucose meal, and 
smaller increases in the glucagon curve. However, 
the glucose tolerance curves were very little dif-
ferent before and after operation (1). 
Liver glycogen concentrations in all those pa-
tients who were later biopsied were not changed. 
In spite of this, in several of our patients and in 
those reported by others, the liver underwent an 
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Figure 6.1. Effect of parenteral hyperalimentation and end-to-side portacaval shunt on the plasma lipids of a patient whose diagnosis 
was type I glycogen storage disease. Note the rapid and relatively complete reversal of all abnormalities. (Reproduced by permission 
from Starzl TE, Putnam CW, Porter Ka, et al. Portal diversion for the treatment of glycogen storage disease in humans. Ann Surg 1973; 
178:52>-.539.) 
obvious reduction in size as measured with liver 
scan planimetry. Even if obvious shrinkage did not 
occur, postoperative biopsies always showed a 
diminution in individual hepatocyte size similar to 
that produced in animals by portacaval shunt (16). 
In contrast to the incomplete relief of hypogly-
cemia, there was profound and permanent relief of 
all components of the hyperlipidemia that is a 
characteristic of type I disease (Fig. 6.1). Correction 
of other metabolic defects was observed, including 
abnormal bleeding, uric acid elevation, and abnor-
mal calcium metabolism (16). These observations 
have been confirmed by others (18-20). 
Growth 
All 10 of our patients had growth retardation 
before portacaval shunt. Increases in height, 
which in most cases had virtually ceased, occurred 
postoperatively at rates in the first year of approx-
imately 0.5 centimeters per month. Quantitative 
measures of growth were obtained with radio-
graphic techniques (16). An example of the results 
is shown in Figure 6.2. Comparison of the wrist 
and hands in this 7-year-old stunted child before 
and II! months after operation showed the phe-
nomenal effects of bone-age doubling. In addition 
to the size change, mineralization occurred, as did 
the appearance of new wrist bones. Circulating 
somatotrophin in these patients was normal. The 
growth spurts may have been at least partially 
attributable to the increased insulin distribution to 
the periphery mentioned earlier, since insulin has 
been recognized to be a major growth hormone, 
comparable in potency to somatotrophin. The sim-
pler possibility that better nutrition was respon-
sible must also be considered. 
Encephalopathy and Other Risks 
One patient exhibited hepatic encephalopathy 8 
years after end-to-side portacaval shunt for type I 
glycogen storage disease, and also developed mul-
tiple filling defects in her enlarged liver. The dis-
eased liver was replaced at transplantation. The 
metabolic abnormalities of type I GSD that had not 
been normalized by the portacaval shunt were 
completely relieved (21). 
One other child developed a blood ammonia 
concentration of 85 micrograms per 100 milliliters 
(normal less than 60 J.Lg/lOO ml for that laboratory), 
but there were no symptoms of encephalopathy. 
This patient died almost 5 years after portacaval 
shunt during an attempt at transcaval radiographic 
visualization of the portacaval anastomosis. Except 
for the slightly elevated blood ammonia concentra-
tion, her standard liver functions were normal. At 
autopsy, the liver had macroadenomatosis, very 
• 
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Figure 6.2. The dramatic wrist and hand bone growth and mineralization in a patient with type I GSD during the first 11! 
postoperative months. The bracket on the left index finger is 5 em in length. (Reproduced by permission from Starzl TE, Putnam CW, 
Porter KA, et al. Portal diversion for the treatment of glycogen storage disease in humans. Am Surg 1973; 178:525-539.) 
similar to that in the child who underwent trans-
plantation. An autopsy finding that had not been 
suspected in life was advanced right ventricular 
hypertrophy and dilatation. The smaller pulmo-
nary arteries and arterioles had medial muscle 
hypertrophy, medial and intimal fibrosis, scattered 
fibrinoid necrosis, and numerous plexiform le-
sions. Such cardiopulmonary complications have 
been documented in other patients with type I 
GSD and other liver diseases (22). 
The macroadenomatosis seen in both of the 
foregoing patients is common in patients with type 
I GSD, and was reported in seven of eight non-
shunted patients aged 3 to 28 years (23). 
Present Status of Portal Diversion 
Portacaval shunt in the treatment of GSD has been 
supplanted by the continuous night feeding sched-
ule advocated by Greene et a1. (24) and Crigler and 
Folkman (25). Failures of this more conservative 
approach should be considered for liver transplan-
tation (see Liver Transplantation, Mechanism of 
Effect, below). 
FAMILIAL HYPERCHOLESTEROLEMIA 
In March 1973, a 12-year-old girl with homozygous 
FH was treated with an end-to-side portacaval 
shunt; her serum cholesterol concentra.tion fell 
markedly (26) (Fig. 6.3). By March 1982, we had 
treated 12 patients with FH in this way (27), eight 
children and four adults. 
In patients with this disease, there is an absence 
or deficiency of cell membrane lipoprotein recep-
tors (28,29) and thus, a switch-off mechanism to 
control lipid (especially cholesterol) synthesis is 
not present. All but two patients were homozy-
gous for the FH abnormality as judged by measure 
of low-density lipoprotein (LDL) receptors on cul-
tured fibroblasts obtained from all patients (28,29). 
The other two patients had heterozygous disease. 
Effect on Serum Lipids 
Total serum cholesterol concentrations fell signifi-
cantly in every patient after portacaval shunt (27). 
The total cholesterol declines ranged from 20% to 
55.4% (average 33.8%) and were maintained 
throughout the period of study. With the fall in 
cholesterol concentration, tendinocutaneous xan-
thomas regressed or disappeared in every patient 
(Fig. 6.4). An anticholesterolemia response after 
portal diversion has been confirmed by numerous 
other authors [summarized in Starzl et a1. (27)], at 
the time tendinocutaneous xanthomas have re-
gressed. Hoeg et a1. (30) have reported a postop-
erative increase in hepatic lipoprotein receptors in 
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Figure 6.3. Serum cholesterol concen-
tration after portacaval shunt in a pa-
tient of our FH series. (Reproduced by 
permission from Starz! TE, Chase HP, 
Putnam CW, Porter KA. Portacaval 
shunt in hyperlipoproteinemia. Lancet 
1973; 2:940-944.) 
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one of our patients. Although an increase of recep-
tors could have contributed to an antilipidemic 
effect of portal diversion, the principal effect prob-
ably was caused by reduced cholesterol and lipo-
protein synthesis (1,3,8,10-12). 
Morbidity 
The invariable and long-lasting lipid lowering in 
our 12 patients was achieved without surgical 
morbidity. The physical development of those chil-




ceeded, and the growth of those who were stunted 
before has moved toward normal. Emotional or 
intellectual deterioration secondary to the portal 
diversion has not occurred, although one child had 
an acute episode of encephalopathy, which was 
managed with diet (27). 
Effect on Cardiovascular Disease 
Reversal of aortic stenosis was seen in two of our 
patients, but regression of atheromas in the coro-




Figure 6.4. The hands of patient 1 of the hyperlipidemia series (A) 2 weeks before and (B) 16 months after portacaval shunt. 
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plished (27). Small and Shipley (31) have examined 
the factors that could preclude the reversal of 
atherosclerosis; some of these, including second-
ary fibrosis, would not be corrected completely by 
the resorption of intravascular xanthomas. 
Present Status of Portal Diversion 
The palliation is incomplete, since restoration of 
normal serum cholesterol values has not been 
achieved in any patient with homozygous disease. 
In contrast, the metabolic abnormalities of FH can 
be completely corrected by the ultimate step of 
liver transplantation, which will become the pre-
ferred method of treatment in the near future (see 
Clinical Applications of Liver Transplantation, be-
low) in medically refractory cases. 
ALPHA,-ANTITRYPSIN DEFICIENCY 
Patients with this disorder have a low level plasma 
aiphal-antitrypsin (an alpha-globulin), a high inci-
dence of pulmonary complications, and an in-
creased incidence of liver disease. The basis for the 
liver injury may be the hepatic production of an 
abnormal alpha I-antitrypsin, which cannot be ef-
fectively transported out of the liver cells and 
which consequently becomes sequestered within 
the hepatocytes near the RER (32). Irritation by the 
entrapped glycoprotein has been the postulated 
cause of the hepatic cirrhosis, portal hypertension, 
and hepatic failure that follow. 
We have performed end-to-side portacaval 
shunt in three children with the cirrhotic liver 
disease of alpha I-antitrypsin deficiency (33). Fol-
low-up reports are available at 6!, 8, and nearly 10 
years. Standard liver function tests have not 
changed greatly since the portacaval shunt, al-
though the plasma ammonia levels have been 
elevated in all three patients. Patient 2 has had 
mental slowness, which may be a symptom of 
encephalopathy. 
The most objective evidence that the natural 
history of the disease was favorably altered came 
from the histopathologic studies of operative and 
postoperative biopsies in patients 2 and 3 (33). In 
patient 2, a biopsy 9 months after the portal 
diversion showed that the number of hepatocytes 
that contained alpha I-antitrypsin globules was di-
minished to 28.5%, compared with 38.2% at the 
time of the original operation. The hepatocytes 
were 22% smaller and the amount of RER in their 
cytoplasm was greatly reduced. 
In patient 3, the percentage of hepatocytes con-
taining alpha I-antitrypsin globules was 44.5% at 
the time of operation, and 48.2 and 38.7% at 7 and 
13 months, respectively, after portacaval shunt. 
The hepatocytes were 15% and 20% smaller at 
these postoperative periods. The percentage of 
hepatocytes containing aiphal-antitrypsin globules 
was reduced to 20.4% in the biopsy taken at 2 
years, 11 months. The hepatocytes remained 20% 
smaller than in the preoperative biopsy, and the 
amount of both RER and smooth endoplasmic 
reticulum in their cytoplasm was reduced. The 
severity of the macronodular cirrhosis was unal-
tered. 
We believe that the portacaval shunt diminished 
the synthesis of the abnormal alpha I-antitrypsin, 
presumably by altering the function of the RER 
and its ribosomes (see Portal Diversion, Mecha-
nism of Effects, above) without commensurately 
reducing the transport of this glycoprotein. With a 
better equilibrium between the production and 
transport of the alphaglobulin, it is possible that its 
intracellular accumulation has been slowed or 
probably even reversed (33). 
No further portacaval shunts have been carried 
out in patients with alpha1-antitrypsin deficiency 
for more than 6 years. It has been established that 
liver transplantation provides a metabolic "cure" 
and that the protein phenotype of the recipient 
becomes that of the donor for the lifetime of the 
graft (see Liver Transplantation, Mechanism of 
Effect, below), 
Liver Transplantation 
Mechanism of Effect 
The use of portal diversion to treat liver-based 
inborn errors of metabolism requires the creation 
of an abnormal physiologic state for the liver in 
order to achieve countervailing metabolic objec-
tives. A more direct and satisfactory approach is to 
provide a phenotypically normal liver. Studies of 
haptoglobin (34-36), group-specific component 
(36,37), and numerous other products of hepatic 
synthesis (21,32,38-40) have shown that liver ho-
mografts permanently retain their original meta-
bolic specificity after transplantation. Conse-
quently, liver transplantation has been recognized 
for a number of years (37,41) as a potentially 
decisive way to treat those inborn errors of metab-
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Table 6.2. Inborn Errors of Metabolism Corrected by Liver Transplantation-Cases from Personal Series 
Longest 
Metabolic Survival 
Disease Cases En::yme Defect Cure (yr) 
Alpha I-antitrypsin defidency 38 Unknown Yes 10 
Wilson's disease 14 Unknown Yes 15V2 
Tyrosinemia 6 Fumarylacetoacetate hydrolase Yes 4V2 
Type IV GSD 4 Amylo-1.4 transglucosidase (branching Yes 1 V2 
enzyme) 
Hemophilia-A 3 Unknown Yes 
Crigler-Najjar syndrome 2 Glucuronyl-transferase Yes 4" 
Familial hypercholesterolemia 2 None: defident lipoprotein receptors Yes 2 
Type I GSD 1 Glucose-6-phosphatase Yes 4 
Niemann-Pick disease 1 Sphingomyelinase Possibly H'l 
Sea-blue histiocyte syndrome 1 Unknown No 4 
Cystic fibrosis 1 Unknown Not studied l'h 
Hemochromatosis 1 Unknown Yes 2 
Type I oxalosis 1 Thiamin-pyrophosphate-<iependent Probably Unknown' 
carboligase 
• Longest survivor reported by Professor H. Wolff, Berlin, East Germany. 
b Patient treated by Dr. Pierre Daloze, Notre Dame Hospital, Montreal; died of neurologic complications . 
• Patient of Professor Roy Caine, Cambridge, England. 
olism that result partly or completely from defects 
in hepatic function. 
In many of the diseases for which liver trans-
plantation has been carried out, a specific enzyme 
is missing as exemplified by the GSDs. With other 
disorders (e.g., Wilson's disease), the pathogene-
sis is not well understood even today (Table 6.2). 
In some of these conditions, the exact role of liver 
was not known until a study of patients after 
transplantation proved that the defect was hepatic. 
In two of these diseases, familial hypercholester-
olemia and hemophilia, the transplantation itself 
became the most powerful of research tools while 
at the same time benefiting the patient. 
Clinical Applications of Liver Transplantation 
The inborn errors of metabolism for which liver 
transplantation has been carried out are shown in 
Table 6.2. In the majority of such patients, the 
inborn error has itself been responsible for damage 
to the liver, in which case the conventional indica-
tion of liver failure prompted the liver replace-
ment. However, a small but particularly interest-
ing minority of transplantations have been carried 
out solely for the purpose of correcting the inborn 
error itself, and in these cases, a morphologically 
normal liver has been removed and replaced with 
a homograft. Examples include familial hyper-
cholesterolemia, congenital oxalosis, and Crigler-
Najjar syndrome. In the following descriptions, 
emphasis is on those inborn errors that were once 
treated with portal diversion, but for which the 
most desirable treatment today probably is liver 
replacement. 
GLYCOGEN STORAGE DISEASE 
An 8-year-old girl with type I GSD underwent an 
end-to-side portacaval shunt in 1973. Although 
she had reasonable palliation from her multiple 
symptoms, she eventually developed hepatic en-
cephalopathy, and in addition, her liver developed 
masses that were suspected of being hepatomas. 
In January 1982, her diseased liver was removed, 
the portacaval shunt was taken down, and a phe-
notypically normal liver was implanted. Her recov-
ery was relatively uncomplicated, and all of the 
metabolic stigmata of type I GSD (mentioned in 
Glycogen Storage Disease, Metabolic Effects, 
above) were corrected (21). Prior to operation, she 
required frequent night feedings, and if she fasted 
for more than a few hours, her blood sugars 
dropped to below 10 mg%. Afterward, she could 
fast indefinitely. Some months postoperatively, 
her portal vein thrombosed, but she developed 
extensive collaterals to the hepatic graft and she 
has had no evidence of encephalopathy or liver 
failure during her 4 postoperative years. 
Four patients with type IV GSD (see Table 6.2) 
have had their cirrhotic livers removed and re-
placed. Two of these children died perioperatively. 
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The other two have normal function 3 and 18 
months postoperatively. A I-year biopsy of the 
child with the longest survival has shown no 
evidence of recurrent disease. 
FAMILIAL HYPERCHOLESTEROLEMIA 
A 6-year-old girl with severe hypercholesterolemia 
and atherosclerosis had two defective genes at the 
LOL receptor locus, as determined by biochemical 
studies of cultured fibroblasts. One gene, inherited 
from the mother, produced no LOL receptors; the 
other gene, inherited from the father, produced a 
receptor precursor that was not transported to the 
cell surface and was unable to bind LOL. The 
patient degraded intravenously administered 1251_ 
LOL at an extremely low rate, indicating that her 
high plasma LOL-cholesterol level was caused by 
defective receptor-mediated removal of LOL from 
plasma. After transplantation of a liver and a heart 
from a normal donor, the patient's plasma LOL-
cholesterol level declined by 81 %, from 988 to 184 
mg%. The fractional catabolic rate for intrave-
nously administered 125I-LOL, a measure of func-
tional LOL receptors in vivo, increased by 2.5-fold. 
Thus, the transplanted liver, with its normal com-
plement of LOL receptors, was able to remove LOL 
cholesterol from plasma at a nearly normal rate. 
We concluded from these observations that a ge-
netically determined deficiency of LOL receptors 
could be largely reversed by liver transplantation. 
These data have underscored the importance of 
hepatic LOL receptors in controlling the plasma 
level of LOL cholesterol in human beings (42). 
The foregoing hypothesis that the disease was 
caused by deficient LOL receptors has not ex-
cluded the further possibility that the hepatocytes 
of the metabolically abnormal liver overproduce 
cholesterol. A second patient, an ll-year-old boy, 
underwent liver transplantation on December 6, 
1985. His serum cholesterol also fell to essentially 
normal levels. Presently, he is on a medical ward 
at the National Institutes of Health undergoing 
extensive postoperative metabolic studies. Al-
though his heart had been gravely damaged by the 
high cholesterol of his disease, heart transplanta-
tion was not required. A residual high-grade ste-
nosis of one of the coronary arteries has been 
treated by an internal mammary artery-coronary 
artery bypass. 
It has become clear that liver transplantation 
"cures" familial hypercholesterolemia. Further-
more, the performance of the liver replacement 
has permitted the most decisive studies on the 
pathogenesis of the disease that have ever been 
possible. 
ALPHA,-ANTITRYPSIN DEFICIENCY 
Serum alpha I-antitrypsin levels, which normally 
are 200 to 300 mg%, usually are about one-tenth of 
this value in patients who develop alpha1-antitryp-
sin-associated liver disease. Patients at risk can be 
identified by Pi (protease inhibitor) phenotypes, 
the ZZ marker usually being associated with the 
liver disease. More than a decade ago, it was 
demonstrated that the serum alpha1-antitrypsin 
levels were brought to normal, and that the new Pi 
type of liver recipient permanently became that of 
the donor (32,41). Alpha1-antitrypsin deficiency 
has been the inborn error of metabolism most 
commonly treated by liver transplantation (see 
Table 6.2). Realization of the effectiveness of liver 
replacement has prompted us to discontinue ef-
forts at portal diversion, particularly since portaca-
val shunts can jeopardize candidacy for the defin-
itive procedure of transplantation. 
OTHER INBORN ERRORS 
Among the first 500 liver transplantations carried 
out by us under cyclosporine-steroid therapy, 
there were almost a dozen inborn errors (see Table 
6.2). One of the most significant observations (in 
1985) has been that classical hemophilia is com-
pletely corrected by liver replacement (43). The 
explanation of hemophilia has been unknown, but 
the predominance of opinion has been that the 
liver was not central to the pathogeneSiS. With the 
simple expedient of liver transplantation, this doc-
trine was overthrown, and subsequent gene probe 
studies have verified the hepatocyte as the location 
of factor VIII production. 
Summary 
Complete portal diversion can palliate at least 
three inborn errors of metabolism, GSO, FH, and 
alpha1-antitrypsin deficiency. However, these 
three liver-based inborn errors of metabolism, as 
well as numerous other inborn errors, can be 
metabolically cured by the transplantation of phe-
notypically normal livers. 
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Editorial Comment 
The chapters that are concerned with inborn errors 
of metabolism relating directly or indirectly to the 
liver, are a well-orchestrated combined effort of 
two leaders in that field, Marshall Kaplan in med-
icine and Thomas Starzl in surgery. 
Dr. Kaplan has presented a wide-ranging disser-
tation on a number of different familial disorders, 
and has then deferred in terms of surgical treat-
ment to the section specifically related to this 
therapeutic approach. 
Dr. Starzl has covered the main inborn errors of 
metabolism (specifically relating to surgical proce-
dures). These include glycogen storage disease, 
familial hypercholesterolemia, alphal-antitrypsin 
deficiency, isolated examples of rare entities such 
as congenital oxalosis, and the Crigler-Najjar syn-
drome. The earlier imaginative approaches to 
some of these metabolic defects by portal diversion 
have contributed over the years, not only to a 
therapeutic program for these children, but also 
toward a better understanding of the abnormal 
metabolic defects. 
Starzl's pioneer work in liver transplantation has 
made this somewhat formidable procedure a more 
acceptable and effective type of therapy. Orthoto-
pic liver transplantation carried out for a number 
of inborn errors in metabolism, as Dr. Starzl points 
out, has replaced portal diversion as the surgical 
therapy in this area. In many of these instances, 
the metabolic defect results in the liver damage, 
which, in turn, proved to be the surgical indication 
for transplantation, but in a number of other 
instances the defect itself was the rationale for 
treatment by liver replacement. It is in this group 
in particular that liver transplantation has not only 
proved to be therapeutically effective, but also has 
contributed enormously to an increasing under-
standing of some of the puzzling enzymatic and 
other defects that are reflected in these inborn 
errors of metabolism. Observations are still emerg-
ing and may have widespread applications, for 
example, the suggested evidence that the hepa-
tocyte is the site of the defect that results in 
classical hemophilia. 
This review provides a succinct but hardly cur-
sory review of a fascinating segment of human 
disease. 
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